Dashboard
Manage Tickers

APRE


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

aprea-to-feature-preliminary-results-from-acesot-1051-trial-through-september-17-in-poster-presentation-at-aacr-nci-eortc
Aprea To Feature Preliminary Results From ...
10/24/2025 12:35:46

3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastroint...

aprea-therapeutics-determines-rp2d-of-1100-mg-once-daily-for-atrn-119-oral-atr-inhibitor-in-monotherapy-arm-of-ongoing-aboya-119-phase-12a-dose-escalation-study-in-patients-with-advanced-solid-tumors
Aprea Therapeutics Determines RP2D Of 1,10...
10/15/2025 12:04:25

ATRN-119 (ATR Inhibitor): RP2D of 1,100 mg once daily identified in ongoing ABOYA-119 dose-escalation studyFurther ATRN-119 mon...

aprea-therapeutics-announces-two-abstracts-on-clinical-programs-apr-1051-and-atrn-119-accepted-for-poster-presentation-at-eortc-nci-aacr-international-conference
Aprea Therapeutics Announces Two Abstracts...
10/14/2025 12:03:39

Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company ...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/17/2025 12:12:13

aprea-therapeutics-q2-eps-053-beats-074-estimate-sales-118111k-down-from-561574k-yoy
Aprea Therapeutics Q2 EPS $(0.53) Beats $(...
08/12/2025 12:11:26

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/23/2025 21:05:58

aprea-therapeutics-presents-apr-1051-preclinical-and-early-clinical-results-in-hpv-head-and-neck-cancer
Aprea Therapeutics Presents APR-1051 Precl...
06/25/2025 13:05:43

Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) model...

aprea-therapeutics-q1-eps-066-up-from-067-yoy-sales-16246k-down-from-38057k-yoy
Aprea Therapeutics Q1 EPS $(0.66) Up From ...
05/14/2025 12:14:08

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.66) per share. This is a 1.49 percent increase over losses of...

aprea-therapeutics-reports-dosing-of-patient-with-hpv-head-and-neck-squamous-cell-carcinoma-in-ongoing-acesot-1051-trial
Aprea Therapeutics Reports Dosing of Patie...
03/31/2025 12:35:38

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
03/31/2025 12:05:38

aprea-therapeutics-q4-eps-049-up-from-092-yoy
Aprea Therapeutics Q4 EPS ($0.49) Up From ...
03/25/2025 12:41:59

aprea-therapeutics-enters-medical-transfer-agreement-with-md-anderson-cancer-center-to-explore-apr-105-as-a-potential-treatment-for-head-and-neck-squamous-cell-carcinoma
Aprea Therapeutics Enters Medical Transfer...
03/11/2025 12:36:23

hc-wainwright--co-reiterates-buy-on-aprea-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Apre...
01/15/2025 16:03:26

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

hc-wainwright--co-reiterates-buy-on-aprea-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Apre...
12/17/2024 12:27:26

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

aprea-therapeutics-announces-twice-daily-dosing-of-patients-on-aboya-119-clinical-trial-of-atrn-119
Aprea Therapeutics Announces Twice Daily D...
12/11/2024 13:31:53

Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's e...

hc-wainwright--co-reiterates-buy-on-aprea-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Apre...
11/18/2024 12:40:52

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

aprea-therapeutics-q3-eps-064-beats-072-estimate-sales-35462m-beat-22500k-estimate
Aprea Therapeutics Q3 EPS $(0.64) Beats $(...
11/07/2024 13:08:29

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(...

hc-wainwright--co-reiterates-buy-on-aprea-therapeutics-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Apre...
10/24/2024 09:39:26

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

aprea-therapeutics-presents-preliminary-findings-on-oral-wee1-inhibitor-apr-1051-at-eortc-nci-aacr-international-conference-on-molecular-targets-and-therapeutics-date-demonstrates-apr-1051-is-safe-and-well-tolerated-with-no-hematologic-toxicity
Aprea Therapeutics Presents Preliminary Fi...
10/23/2024 12:35:49

Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical n...

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
10/15/2024 16:32:12

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION